NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

$728.60

+3.55 (+0.49%)

(As of 05/30/2023 ET)

Compare

Today's Range: $717.88
▼
$729.45
50-Day Range: $725.00
▼
$830.35
52-Week Range: $538.01
▼
$837.55

Volume: 497,015 shs
Average Volume: 551,006 shs
Market Capitalization: $79.66 billion

P/E Ratio: 19.80
Dividend Yield: N/A
Price Target: $850.21

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 17.2% Upside
$854.13 Price Target
Short Interest: Healthy
1.11% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.97
Upright™ Environmental Score
News Sentiment: 0.72
Based on 12 Articles This Week
Insider Trading: Selling Shares
$10.22 M Sold Last Quarter
Proj. Earnings Growth: 4.86%
From $34.76 to $36.45 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

106th out of 1,009 stocks

Pharmaceutical Preparations Industry

39th out of 494 stocks

3.4

Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.74, and is based on 18 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $854.13, Regeneron Pharmaceuticals has a forecasted upside of 17.2% from its current price of $728.60.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.11% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Regeneron Pharmaceuticals has recently increased by 2.54%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Regeneron Pharmaceuticals has received a 47.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Cardiovascular system medication (C)" products. See details.
Environmental Sustainability
The Environmental Impact score for Regeneron Pharmaceuticals is -1.97.

3.2

News and Social Media Coverage

News Sentiment
Regeneron Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Regeneron Pharmaceuticals this week, compared to 11 articles on an average week.
Search Interest
23 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.
MarketBeat Follows
11 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,218,737.00 in company stock.
Percentage Held by Insiders
Only 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
84.25% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to grow by 4.86% in the coming year, from $34.76 to $36.45 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 19.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.74.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 19.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.00.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

May 5, 2023 | marketbeat.com

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

May 27, 2023 | americanbankingnews.com

Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $850.91

May 31, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 26, 2023 | finance.yahoo.com

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

May 26, 2023 | msn.com

Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%

May 25, 2023 | msn.com

Regeneron Pharmaceuticals Unusual Options Activity For May 25

May 25, 2023 | finance.yahoo.com

Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations

May 25, 2023 | finance.yahoo.com

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

May 31, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 25, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group

May 25, 2023 | finance.yahoo.com

14 Best Biotech Stocks To Buy According To Hedge Funds

May 22, 2023 | benzinga.com

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

May 22, 2023 | msn.com

Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained

May 22, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at StockNews.com

May 22, 2023 | reuters.com

Sanofi: smoker's lung drug benefit was swift and sustained in trial

May 20, 2023 | finance.yahoo.com

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years

May 19, 2023 | msn.com

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

May 19, 2023 | benzinga.com

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

May 19, 2023 | finance.yahoo.com

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

May 18, 2023 | finance.yahoo.com

Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation

May 16, 2023 | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 | msn.com

RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation

May 16, 2023 | finance.yahoo.com

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

May 13, 2023 | seekingalpha.com

Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript

May 11, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at StockNews.com

May 11, 2023 | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $935.00 at Guggenheim

May 9, 2023 | finance.yahoo.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings: 2/03/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:REGN
CUSIP: 75886F10
CIK: 872589
Web: www.regeneron.com
Phone: (914) 847-7000
Fax: 914-347-2113
Employees: 11,851
Year Founded: 1988

Price Target and Rating

Average Stock Price Forecast: $850.21
High Stock Price Forecast: $1,050.00
Low Stock Price Forecast: $625.00
Forecasted Upside/Downside: +16.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 24 Analysts

Profitability

EPS (Most Recent Fiscal Year): $36.80
Trailing P/E Ratio: 19.80
Forward P/E Ratio: 20.96
P/E Growth: 2.32
Net Income: $4.34 billion
Net Margins: 33.81%
Pretax Margin: 37.64%
Return on Equity: 20.41%
Return on Assets: 15.79%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 5.45
Quick Ratio: 4.67

Sales & Book Value

Annual Sales: $12.17 billion
Price / Sales: 6.54
Cash Flow: $44.75 per share
Price / Cash Flow: 16.28
Book Value: $207.31 per share
Price / Book: 3.51

Miscellaneous

Outstanding Shares: 109,330,000
Free Float: 99,673,000
Market Cap: $79.66 billion
Optionable: Optionable
Beta: 0.23

Social Links

Key Executives

Leonard S. Schleifer
Co-President, Chief Executive Officer & Director

George Damis Yancopoulos
Co-President, Director & Chief Scientific Officer

Patrice Gilooly
Senior VP-Quality Assurance & Operations

Robert E. Landry
Chief Financial Officer & Executive VP-Finance

Neil Stahl
Executive VP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?: 24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.
What is Regeneron Pharmaceuticals' stock price forecast for 2023?: 24 analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $625.00 to $1,050.00. On average, they anticipate the company's share price to reach $850.21 in the next year. This suggests a possible upside of 16.7% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.
How have REGN shares performed in 2023?: Regeneron Pharmaceuticals' stock was trading at $721.49 at the start of the year. Since then, REGN stock has increased by 1.0% and is now trading at $728.60.
View the best growth stocks for 2023 here.
When is Regeneron Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our REGN earnings forecast.
How were Regeneron Pharmaceuticals' earnings last quarter?: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.18 by $4.38. The biopharmaceutical company earned $3.41 billion during the quarter, compared to analyst estimates of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 33.81% and a trailing twelve-month return on equity of 20.41%. The company's revenue for the quarter was down 31.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $23.72 EPS.
Read the conference call transcript.
What ETFs hold Regeneron Pharmaceuticals' stock?: ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust US Equity Opportunities ETF (FPX), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Simplify Health Care ETF (PINK), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA) and Invesco Dynamic Biotechnology & Genome ETF (PBE).
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?: 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.
What other stocks do shareholders of Regeneron Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?: Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
Who are Regeneron Pharmaceuticals' major shareholders?: Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (8.63%), BlackRock Inc. (8.61%), State Street Corp (4.48%), Dodge & Cox (2.18%), Geode Capital Management LLC (2.03%) and Price T Rowe Associates Inc. MD (1.99%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.
How do I buy shares of Regeneron Pharmaceuticals?: Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Regeneron Pharmaceuticals' stock price today?: One share of REGN stock can currently be purchased for approximately $728.60.
How much money does Regeneron Pharmaceuticals make?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $79.66 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $36.80 on an earnings per share basis.
How many employees does Regeneron Pharmaceuticals have?: The company employs 11,851 workers across the globe.
Does Regeneron Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

Regeneron Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

REGN Stock News Headlines

REGN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

REGN Stock - Frequently Asked Questions

Overall MarketRank^™